Previous 10 | Next 10 |
2024-03-13 17:07:28 ET Gainers: Turtle Beach ( HEAR ) +22% . SoundHound ( SOUN ) +12% . Robinhood Markets ( HOOD ) +9% . Recursion Pharmaceuticals ( RXRX ) +7% . Pyxis Oncology ( PYXS ) +3% . Losers: WW International ( ...
2024-03-12 15:08:43 ET More on S&P 500 Index: The Great Paradox Of The U.S. Market Stocks Rally As Implied Volatility Drops Following Hot CPI Report February CPI: Back-To-Back Hot Inflation May Extend The Fed's Pause Nasdaq, S&P, Dow climb as latest C...
LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood. Set to formally open in June ...
2024-03-07 10:28:00 ET On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter ear...
2024-03-04 21:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare Disease Day event at its headquarters on February 29 and virtually in partnership with Allian...
2024-02-28 18:44:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) couldn't get over the hump of Hump Day. Following the release of the next-generation biotech's latest set of quarterly and annual results, investors traded out of its stock, to the point where the shares lost almost 17%...
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the near-term In-licensed a program (Target Epsilon) that emerged from our fibrosis collabora...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...
2024-02-23 06:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,...